In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
about
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.Pemetrexed disodium in ovarian cancer treatment.Clinical pharmacology and pharmacogenetics of gemcitabine.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Progress in personalizing chemotherapy for bladder cancerSynthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology GroupHuman nucleoside transporters: biomarkers for response to nucleoside drugs.Drug transporter pharmacogenetics in nucleoside-based therapies.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
P2860
Q33914993-3814FD26-5C00-49C2-B7B7-F1E3FE59C35FQ34253505-8E5C6B23-AE16-49A3-8C4F-51A1254A030FQ34985979-AF9B5512-C506-4992-A76B-969E25190C33Q35066350-EE5B5E61-92AC-4277-AB46-DB879C91453DQ35237773-1B14F198-D3FB-4B93-A54E-182D333EF7E0Q35779460-86747400-28FC-4327-AA67-B5A7A4092A46Q35909171-22D7C18C-E9F3-456B-8F40-2B36E7592608Q36342657-32D9FDA9-E7B3-4612-92E7-E9F7046B5C58Q36610851-C5864BE4-B3F8-41FD-90BF-CBF0480F0F24Q36817080-ACC77D55-2D30-43D4-9E19-E7D218A1CD56Q37090628-D494094E-6D3E-498F-9954-0E4609CF4000Q37172835-236C6857-5447-4976-9ECC-61B86EA63301Q37698437-5127DBCE-813E-4B02-A974-8265F25B73A7Q37760954-D765AC72-8C1E-4530-B339-817A1A067721Q38312045-0A605C70-48E4-4623-B5CA-7AD0F94FD31CQ40004108-98B6B958-A8DD-4657-AEBB-D7945EA6EB26Q43489127-38671392-BD55-44B0-B83D-6CECBFBBFC6EQ45220444-09DED785-C45E-4823-B44A-89B3C5E62A83
P2860
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
In vitro synergistic cytotoxic ...... ne in bladder cancer patients.
@ast
In vitro synergistic cytotoxic ...... ne in bladder cancer patients.
@en
type
label
In vitro synergistic cytotoxic ...... ne in bladder cancer patients.
@ast
In vitro synergistic cytotoxic ...... ne in bladder cancer patients.
@en
prefLabel
In vitro synergistic cytotoxic ...... ne in bladder cancer patients.
@ast
In vitro synergistic cytotoxic ...... ne in bladder cancer patients.
@en
P2093
P2860
P50
P356
P1476
In vitro synergistic cytotoxic ...... ine in bladder cancer patients
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603242
P407
P50
P577
2006-07-25T00:00:00Z